Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Warfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 10/20 | 1.00 |
| ▸ | ALB | P02768 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PCSK7 | Q16549 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | BRD4 | O60885 | 1/20 | 0.68 |
| ▸ | NQO1 | P15559 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Warfarin SCHEMBL3792087 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3689 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL662875 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2139452 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4439794 | 1.00 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4757598 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL34347 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2597774 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL13278154 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL5016404 | 0.99 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3578542-B1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-11-12 | — | — | EP | claimed |
| EP-3578543-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-08-20 | — | — | EP | claimed |
| EP-3578541-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-05-28 | — | — | EP | claimed |
| CN-119129418-A | Novel power system power planning method based on reliability evaluation feasible region | 哈尔滨工业大学 | 2024-12-13 | — | — | CN | claimed |
| CN-119103819-A | Alternating airflow heat pump dehumidification drying device and control method thereof | 北京科技大学 | 2024-12-10 | — | — | CN | claimed |
| US-11845735-B2 | Method for synthesizing (RS)-Warfarin | BATOOIE NASIM (IR) | 2023-12-19 | — | — | US | claimed |
| WO-2023094911-A1 | METHOD FOR SYNTHESIZING (RS)-WARFARIN | BATOOIE NASIM (IR) | 2023-06-01 | — | — | WO | claimed |
| US-20230167079-A1 | METHOD FOR SYNTHESIZING (RS)-WARFARIN | Batooie, Nasim (IR) | 2023-06-01 | — | — | US | claimed |
| US-11309064-B2 | Individualized dosing technique with multiple variables | Hurst, Katherine L. (US) | 2022-04-19 | — | — | US | claimed |
| WO-2026105126-A1 | DNA-BASED MECHANOSENSITIVE DELIVERY AGENTS AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089753-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089751-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-11352404-B2 | Phosphatidylserine targeting fusion molecules and methods for their use | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220168316-A1 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | CAMP4 THERAPEUTICS CORPORATION | 2022-06-02 | — | — | US | disclosed |
| US-20220169672-A1 | COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2022-06-02 | — | — | US | disclosed |
| US-11309064-B2 | Individualized dosing technique with multiple variables | Hurst, Katherine L. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-11266655-B2 | Methods and compositions for treating urea cycle disorders | CAMP4 THERAPEUTICS CORPORATION (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169672-A1 | COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER | KLK3, AR, ACP3 | VKORC1 1174/4885CYP2C9 3928/4885ALB 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.